Plain-English translation of NCT06585410 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to treat early-stage cutaneous squamous cell carcinoma (CSCC), a common type of skin cancer. works by helping your body's own immune system recognize and kill cancer cells. The study will compare how well this medication works when injected directly into the tumor compared to having the tumor surgically removed.
Currently, surgery is the standard treatment for early-stage skin cancer, but it leaves a scar and requires recovery time. This trial is testing whether the medication could offer patients an effective alternative that might avoid surgery altogether.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either receive injections of the medication directly into your tumor or to have surgery to remove it. You will visit the clinic multiple times for treatment and follow-up visits to check how well the treatment is working and to monitor for any side effects. The study will track how your tumor responds over time and compare the results between the two groups.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States